Click Below to Return to Drug Transparency Home Page:

 

LC-DT Home
 

 

Subscribe/Unsubscribe to LISTSERV email notifications for Nevada Drug Transparency Information and Updates Here: 

 Subscribe to Drug Transparency LISTSERV                     Unsubscribe to Drug Transparency LISTSERV

Drug Tranparency - Essential Lists, Reports & Resources

List of Essential Drugs for Treating Diabetes ~ SB 539 Section 3.6 & NRS 439B.630

2017 List of Essential Diabetes Drugs v02.13.2018

Senate Bill No. 539 was passed during the 2017 legislative session, requiring the Department to compile a list of prescription drugs that the Department determines to be essential for treating diabetes in this State and the wholesale acquisition cost of each drug on the list. The list must include, without limitation, all forms of insulin and biguanides marketed for sale in this State.
pdf document

Drug Pricing Report ~ SB 539 Section 4.3 & NRS 439B.635

Senate Bill No. 539 was passed during the 2017 legislative session, requiring the Department to analyze the information submitted pursuant to sections 3.8, 4 and 4.2 of this act and compile a report on the price of the prescription drugs that appear on the most current lists compiled by the Department pursant to section 3.6 of this act, the reasons for any increase in those prices and the effect of those prices on overall spending on prescription drugs in the State. The report may include, without limitation, opportunities for persons and entities in this State to lower the cost of drugs for the treatment of diabetes while maintaining access to such drugs.

Essential Diabetes Drugs Price Increase Report

Essential Diabetes Drugs Prices Increase Final Report – September 11, 2018 (Draft Report, August 24, 2018). This 2018 report of essential medications reflects those drugs that showed a price increase above the thresholds established in the law.
pdf documentpdf document

Analysis of Essential Diabetes Drugs that had a Price Increase

Analysis of Essential Diabetes Drugs that had a Price Increase - September 30, 2018
pdf document

Pharmaceutical Sales Representatives Report ~ SB 539 Section 4.6(5) & NRS 439B.660

Compensation and Samples Distributed by Pharmaceutical Sales Representatives in Nevada v06.01.2018

Senate Bill No. 539 was passed during the 2017 legislative session, requiring the Department to compile a report on the activities of pharmaceutical sales representatives in this state with a list of prescription drugs used to treat diabetes and requiring each pharmaceutical sales representative to report samples as well as compensation in excess of $10 provided to health care providers within the State of Nevada.
pdf document

Drug Transparency Regulations ~ SB 539 & NRS 439B

Nevada Revised Statutes ~ Chapter 439B

The Nevada Revised Statutes (NRS) are all the current codified laws of the State of Nevada. Nevada law consists of the Constitution of Nevada (the state constitution) and Nevada Revised Statutes.
link document

Secretary of State Adopted Regulations

The adopted regulation outlines how the Department of Health and Human Services will support submission of certain reports by manufacturers of prescribtion drugs, pharmacy benefit mangers and pharmaceutical sales representatives by providing forms online. It describes the process by which a manufacturer or pharmacy benefit manager can submit a request for confidentiality covering certain information. Lastly, it describes procedures the Department will follow when public information requests for information are filed and for which a confidentiality request has been submitted.
pdf document

Nevada Senate Bill (SB) No. 539 Legislative Text

AN ACT relating to prescription drugs; requiring the Department of Health and Human Services to compile certain lists of certain prescription drugs that are used to treat diabetes; requiring the manufacturer of a drug included on such lists and a pharmacy benefit manager to provide certain information to the Department; requiring the Department to compile a report based on such information; requiring a manufacturer of prescription drugs to submit a list of each pharmaceutical sales representative who markets prescription drugs to certain persons in this State; prohibiting a pharmaceutical sales representative who is not included on such a list from marketing prescription drugs on behalf of a manufacturer; requiring each pharmaceutical sales representative included on such a list to report certain information to the Department; requiring certain nonprofit organizations to report to the Department certain information concerning certain contributions and benefits received from drug manufacturers, insurers and pharmacy benefit managers or trade and advocacy groups for such entities; requiring the Department to place certain information on its Internet website; authorizing the Department to impose an administrative penalty in certain circumstances; providing that certain information does not constitute a trade secret; imposing certain requirements on a pharmacy benefit manager; requiring a private school to allow a pupil to keep and self-administer certain drugs; requiring certain insurers to provide certain notice to insureds; providing penalties; and providing other matters properly relating thereto.
link document